Johnson & Johnson (NYSE:JNJ – Get Free Report) had its price objective boosted by investment analysts at JPMorgan Chase & Co. from $285.00 to $300.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 10.89% from the company’s current price.
JNJ has been the subject of a number of other reports. Royal Bank Of Canada cut their price target on Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating for the company in a report on Wednesday, October 14th. HSBC raised their price objective on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Johnson Rice lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, October 21st. UBS Group set a $270.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 14th. Finally, Leerink Partners cut their target price on shares of Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating for the company in a research note on Wednesday, October 14th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $276.54.
View Our Latest Stock Report on Johnson & Johnson
Johnson & Johnson Trading Up 1.3%
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities research analysts forecast that Johnson & Johnson will post 11.12 earnings per share for the current year.
Insider Activity
In other Johnson & Johnson news, EVP Elizabeth Forminard sold 13,072 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $284.39, for a total value of $3,717,546.08. Following the completion of the sale, the executive vice president owned 16,994 shares in the company, valued at approximately $4,832,923.66. This trade represents a 43.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. The trade was a 56.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.16% of the company’s stock.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of JNJ. Outlook Capital Management LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter worth about $28,000. Navigoe LLC boosted its position in shares of Johnson & Johnson by 60.4% during the 3rd quarter. Navigoe LLC now owns 146 shares of the company’s stock valued at $38,000 after acquiring an additional 55 shares in the last quarter. Matrix Trust Co increased its stake in Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after acquiring an additional 54 shares during the period. Montgomery Financial Services LLC bought a new stake in Johnson & Johnson in the second quarter valued at about $43,000. Finally, Hanseatic Management Services Inc. acquired a new position in Johnson & Johnson in the third quarter worth about $52,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.
Key Stories Impacting Johnson & Johnson
Investors following JNJ have been watching these stories:
- Positive Sentiment: Phase 4 results for TREMFYA in axial psoriatic arthritis met key endpoints, with significant symptom improvement and more than twice the placebo reduction in MRI-assessed inflammation. The data could strengthen the drug’s commercial prospects. Article
- Positive Sentiment: J&J announced the first U.S. commercial installation of its OTTAVA surgical robot at a Houston hospital, an early step in bringing the platform to market and expanding its surgical-technology business. Article
- Negative Sentiment: A Louisiana appeals court upheld a multimillion-dollar talc verdict and increased damages, reinforcing ongoing litigation exposure for J&J. Article
Johnson & Johnson Company Profile
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
Further Reading
- Five stocks we like better than Johnson & Johnson
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
